Wall Street analysts said that the death could amplify patient hesitancy to use Elevidys, given that both this and SRP-9004 use the same delivery vehicle known as adeno-associated virus vector.

Elevidys scored an accelerated FDA approval in June 2023, quickly ranking as one of the world’s most expensive drugs with a list price of $3.2 million. As a gene therapy, the treatment was ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite ...

The FDA says it has asked Sarepta Therapeutics to voluntarily stop all shipments of Elevidys after the company confirmed a third patient death related to one of its gene therapies. Biotech's ...

The death “could lead to greater scrutiny of SRP-9003’s safety profile” ahead of Sarepta’s submission and “could affect commercial interest, if approved,” the William Blair team said.

Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...

The FDA asked Sarepta Therapeutics to halt shipments of its Elevidys gene therapy after a patient's death linked to a similar treatment. Sarepta will continue shipments for ambulatory patients but ...

Sarepta to continue Elevidys shipments despite FDA request to halt Jul. 19, 2025 7:30 AM ET Sarepta Therapeutics, Inc. (SRPT) Stock RHHBY, RHHBF By: Dulan Lokuwithana, SA News Editor 29 Comments ...

Additionally, in a timely manner, Sarepta reported this ALF event as a life-threatening case to FDA on June 20, 2025, and further followed up with notification to FDA of the death on July 3, 2025 ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.

(Reuters) -Shares of Sarepta Therapeutics declined 26% to $16.17 in premarket trading on Friday on media reports of a patient death after receiving one of the company's gene therapies, making it ...